Mammalian target of rapamycin (mTOR) inhibitors
-Pipeline Insights, 2016 report provides comprehensive insights about pipeline
drugs accross this mechanism of action. Key objective of the report is to
establish the understanding for all the pipeline drugs that fall under
Mammalian target of rapamycin (mTOR) inhibitors. The Report gives insights on
20+ products, 18+ companies that are active in this field and 5 different
technologies used in the pipeline.
This report also provides information on the
therapeutic development based on the mTOR inhibitors dealing with all the
pipeline drugs, comparative analysis mTOR inhibitors at various stages covering
Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and
unknown stages, therapeutics assessment by monotherapy and combination products
and molecule type drug information.
It covers 5+ therapy areas that are being targeted
by mTOR inhibitors. The report also covers the company’s information involved
in the therapeutic development of the products. It also has highlighted the
discontinued and dormant products. This Report will help you to identify
emerging players with potentially strong product information, licensing
opportunities and helps you to create effective counter-strategies to gain
competitive advantage.
Report Highlights:
- The new report, provides a Mammalian Target of Rapamycin (Mtor) Inhibitors Landscape across the globe.
- The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information.
- Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages.
- Coverage of the Mammalian Target of Rapamycin (Mtor) Inhibitors based pipeline on the basis of target, MOA, route of administration, technology involved and molecule type.
- The report reviews key players involved in the therapeutics development for Mammalian Target of Rapamycin (Mtor) Inhibitors and also provide company profiling.
- Pipeline products coverage based on various stages of development from NDA filings to discovery.
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.
Spanning over 100 pages, 13 Tables and
15 Figures “Mammalian Target of Rapamycin (Mtor) Inhibitors, Pipeline
Insights, 2016” report
covers Mammalian target of rapamycin (mTOR) inhibitors Overview, Pipeline
Therapeutics, Comparative Analysis, Product Description, Comparative Analysis,
Research and Development, Therapeutic Assessment, Appendix. This report Covered
5 Companies - Santen Pharmaceutical Co, Ltd., Pfizer, Piqur Therapeutics AG,
Pfizer, Macusight.
For
more information Visit at: http://mrr.cm/JRH
Find all Drug Discovery Reports at: http://www.marketresearchreports.com/drug-discovery
No comments:
Post a Comment
Note: only a member of this blog may post a comment.